Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study.

ABSTRACT:

Background

Fruquintinib has been approved by the Food and Drug Administration for refractory metastatic colorectal cancer (mCRC). In clinical practice, fruquintinib is sometimes used in combination with other drugs, but its efficacy and safety are still unknown. In this study, we present a comprehensive analysis of the real-world treatment modalities involving fruquintinib in late-line settings for mCRC across six centers in China.

Patients and methods

Patients with refractory mCRC who received fruquintinib treatment in six centers in China between 1 January 2021 and 31 June 2022 were included in this study. Patients were categorized into two cohorts: the monotherapy group (treated solely with fruquintinib) and the combined group (received fruquintinib combined with chemothe

SUBMITTER: Xu D 

PROVIDER: S-EPMC11693424 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature